Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells

Zhiquan Wang, Huihuang Yan, Justin C. Boysen, Charla R. Secreto, Esteban Braggio, Susan L. Slager, Sameer A. Parikh, Neil E. Kay

Blood (2021) 138 (Supplement 1): 3313.

https://doi.org/10.1182/blood-2021-153214

Published: 2021

Journal Articles

Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia

Zhiquan Wang, PhD, Justin C. Boysen, Huihuang Yan, PhD, Charla R. Secreto, Sameer A. Parikh, MD, Saad S. Kenderian, MB, ChB, Wei Ding, MD PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140309

Published: 2020

Journal Articles

Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136550

Published: 2020

Journal Articles

Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation

Prajish Iyer, PhD, Lu Yang, PhD, Zhi-Zhang Yang, PhD, Charla R. Secreto, Sutapa Sinha, PhD, Neil E. Kay, MD, Stephen M. Ansell, MD PhD, Lili Wang, MDPhD, Wei Ding, MD PhD, Hyojin Kim, PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-138601

Published: 2020

Journal Articles

Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib

Hanyin Wang, MD, Shulan Tian, MS, PhD, Qing Zhao, Wendy Blumenschein, Jennifer H. Yearley, PhD, Charla R. Secreto, Sutapa Sinha, PhD, Timothy G. Call, MD, Yucai Wang, MDPhD, Sameer A. Parikh, MD, Saad S. Kenderian, MB, ChB, Rong He, MD, Jose F. Leis, MD PhD, Min Shi, MDPhD, Neil E. Kay, MD, Susan L. Slager, PhD, Esteban Braggio, PhD, Huihuang Yan, PhD, Wei Ding, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136172

Published: 2020

Journal Articles

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2019) 134 (Supplement_1): 1739.

https://doi.org/10.1182/blood-2019-121772

Published: 2019

Journal Articles

A Role for TNF-α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction

Bryce A Manso, BSc, Jordan Krull, Kimberly Gwin, Petra Lothert, Charla R Secreto, Wei Ding, MD PhD, Sameer A. Parikh, MD, Anne J Novak, PhD, Neil E. Kay, MD, Kay L. Medina, PhD

Blood (2019) 134 (Supplement_1): 4276.

https://doi.org/10.1182/blood-2019-130518

Published: 2019

Journal Articles

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Sutapa Sinha, PhD, Tammy Price-Troska, BS, Shulan Tian, MS, PhD, Charla R Secreto, Xiaosheng Wu, MD, Timothy G. Call, MD, Rong He, MD, Sameer A. Parikh, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Huihuang Yan, PhD, Karen L Rech, MD, Minetta C Liu, MD, Stephen M. Ansell, MD PhD, Neil E. Kay, MD, Wei Ding, MD PhD

Blood (2018) 132 (Supplement 1): 586.

https://doi.org/10.1182/blood-2018-99-112575

Published: 2018

Journal Articles

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2018) 132 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2018-99-110981

Published: 2018

Journal Articles

Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment

Bryce Manso, BSc, Kimberly Gwin, Charla R Secreto, Henan Zhang, MD, Wei Ding, MD PhD, Sameer A. Parikh, MD, Neil E. Kay, MD, Kay L. Medina, PhD

Blood (2018) 132 (Supplement 1): 3132.

https://doi.org/10.1182/blood-2018-99-118916

Published: 2018

Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Blood (2017) 129 (26): 3419–3427.

https://doi.org/10.1182/blood-2017-02-765685

Published: 2017

Includes: Supplemental data

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Blood (2016) 128 (22): 4392.

https://doi.org/10.1182/blood.V128.22.4392.4392

Published: 2016

Journal Articles

Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.

Henan Zhang, MD, Kimberly A Gwin, Charla R Secreto, Wei Ding, MD PhD, Kay Medina, PhD, Neil E. Kay, MD

Blood (2016) 128 (22): 2013.

https://doi.org/10.1182/blood.V128.22.2013.2013

Published: 2016

Journal Articles

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

Sutapa Sinha, PhD, Justin C Boysen, Kari G. Chaffee, MS, Brian F Kabat, Susan L. Slager, PhD, Sameer A. Parikh, MD, Charla R Secreto, Tait D. Shanafelt, MD, Jose F. Leis, MD PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2016) 128 (22): 2020.

https://doi.org/10.1182/blood.V128.22.2020.2020

Published: 2016

Journal Articles

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Henan Zhang, MD, Shulan Tian, Esteban Braggio, PhD, Andrew L Feldman, MD, Rhett P. Ketterling, MD, Rong He, MD, Timothy G. Call, MD, Thomas E. Witzig, MD, Sameer A. Parikh, MD, Yi Lin, MD PhD, Charla R Secreto, Emma I Andersson, MSc, Satu Mustjoki, MD PhD, Alexandra Schrader, Marco Herling, MD PhD, Huihuang Yan, Ph. D, Wei Ding, MD PhD

Blood (2016) 128 (22): 4103.

https://doi.org/10.1182/blood.V128.22.4103.4103

Published: 2016

Journal Articles

Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression

Asish K. Ghosh, Charla R. Secreto, Traci R. Knox, Wei Ding, Debabrata Mukhopadhyay, Neil E. Kay

Blood (2010) 115 (9): 1755–1764.

https://doi.org/10.1182/blood-2009-09-242719

Published: 2010

Includes: Supplemental data

Journal Articles

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Farrukh T. Awan, Neil E. Kay, Melanie E. Davis, Wenting Wu, Susan M. Geyer, Nelson Leung, Diane F. Jelinek, Renee C. Tschumper, Charla R. Secreto, Thomas S. Lin, Michael R. Grever, Tait D. Shanafelt, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, Gerard Lozanski, John C. Byrd, David M. Lucas

Blood (2009) 113 (3): 535–537.

https://doi.org/10.1182/blood-2008-08-173450

Published: 2009

Journal Articles

Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.

Wei Ding, MD, Grzegorz S. Nowakowski, MD, Jennifer L. Abrahamzon, Linda E. Wellik, Asish K. Ghosh, PhD, Charla R. Secreto, Kay L. Medina, PhD, Tait D. Shanafelt, MD, Clive S. Zent, MD, Neil E. Kay, MD

Blood (2007) 110 (11): 337.

https://doi.org/10.1182/blood.V110.11.337.337

Published: 2007

Journal Articles

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clive S. Zent, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Charla R. Secreto, Deborah A. Bowen, RN, Susan M. Geyer, PhD, Brian F. Kabat, Betsy R. LaPlant, Wenting Wu, PhD, Neil E. Kay, MR

Blood (2007) 110 (11): 2050.

https://doi.org/10.1182/blood.V110.11.2050.2050

Published: 2007

Journal Articles

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Clive S. Zent, MD, Nancy D. Bone, Timothy G. Call, MD, Tait D. Shanafelt, MD, Susan M. Geyer, PhD, Charla R. Secreto, Diane F. Jelinek, PhD, Gordon W. Dewald, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2829.

https://doi.org/10.1182/blood.V108.11.2829.2829

Published: 2006

NARROW

B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells

Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia

Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma

Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation

Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

A Role for TNF-α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only